Endometrial Priming for Embryo Transfer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by Parc de Salut Mar
Sponsor:
Information provided by (Responsible Party):
Parc de Salut Mar
ClinicalTrials.gov Identifier:
NCT01430650
First received: June 20, 2011
Last updated: February 14, 2013
Last verified: February 2013

June 20, 2011
February 14, 2013
July 2010
June 2013   (final data collection date for primary outcome measure)
Difference between day means in endometrial priming to achieve 7 mm. [ Time Frame: 11-16 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01430650 on ClinicalTrials.gov Archive Site
  • Biochemical Pregnancy rate [ Time Frame: 26-30 days ] [ Designated as safety issue: No ]
    To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embryonary transference and multiply by 100.
  • The patient's adherence to the recommended treatment. [ Time Frame: 1-16 days ] [ Designated as safety issue: No ]
  • Biochemical Pregnancy rate [ Time Frame: 26-30 days ] [ Designated as safety issue: No ]
    To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embrionary transference and multiply by 100.
  • The patient's adherence to the recommended treatment. [ Time Frame: 1-16 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Endometrial Priming for Embryo Transfer
A Randomised Control Trial to Evaluate Efficacy and Safety of Two Different Protocols of Endometrial Priming for Embryo Transfer.

The aim of this trial is compare two different endometrial priming protocols

  • women that receive oral estrogens
  • women that receive transdermal estrogens
Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Sterility
  • Drug: Oral strogen
    2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
  • Drug: Transdermal strogen
    One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
  • Experimental: Oral strogen
    Intervention: Drug: Oral strogen
  • Experimental: Transdermal strogen
    Intervention: Drug: Transdermal strogen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
134
December 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women between 18-50 years old with desire of children and needs of embryo transfer.
  • Plasma prolactin less than 30.
  • Uterine cavity that allow pregnancy, body mass index between 20-30.
  • And signed consent inform.

Exclusion Criteria:

  • History of estrogen dependent cancer, unknown origin vaginal bleeding.
  • Ovarian cyst.
  • Contraindications to be pregnant.
  • Estrogen allergy.
Female
18 Years to 50 Years
No
Contact: Miguel Angel Checa, PhD 0034 93 248 31 29 macheca@parcdesalutmar.cat
Spain
 
NCT01430650
UREP-PREPENDO-2010
No
Parc de Salut Mar
Parc de Salut Mar
Not Provided
Not Provided
Parc de Salut Mar
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP